Your browser is no longer supported. Please, upgrade your browser.
Inotiv, Inc.
Index- P/E- EPS (ttm)-0.42 Insider Own6.90% Shs Outstand14.66M Perf Week-9.11%
Market Cap770.21M Forward P/E36.53 EPS next Y1.44 Insider Trans0.37% Shs Float7.86M Perf Month18.52%
Income-5.10M PEG- EPS next Q0.52 Inst Own55.80% Short Float26.81% Perf Quarter101.96%
Sales75.30M P/S10.23 EPS this Y-467.40% Inst Trans27.24% Short Ratio10.03 Perf Half Y99.20%
Book/sh6.07 P/B8.67 EPS next Y308.10% ROA-5.70% Target Price64.50 Perf Year711.88%
Cash/sh1.69 P/C31.18 EPS next 5Y- ROE-18.50% 52W Range6.32 - 60.66 Perf YTD327.72%
Dividend- P/FCF- EPS past 5Y-40.40% ROI-8.10% 52W High-13.27% Beta2.14
Dividend %- Quick Ratio1.00 Sales past 5Y21.60% Gross Margin32.40% 52W Low732.44% ATR4.73
Employees150 Current Ratio1.00 Sales Q/Q44.90% Oper. Margin-4.60% RSI (14)55.09 Volatility12.56% 9.23%
OptionableNo Debt/Eq0.50 EPS Q/Q-91.80% Profit Margin-6.80% Rel Volume1.15 Prev Close55.25
ShortableYes LT Debt/Eq0.32 Earnings- Payout- Avg Volume209.85K Price52.61
Recom1.00 SMA20-0.93% SMA5024.44% SMA20082.07% Volume241,763 Change-4.78%
Sep-20-21Initiated Craig Hallum Buy $45
Nov-29-21 04:21PM  
Nov-10-21 08:33AM  
Nov-08-21 10:56AM  
Nov-05-21 01:33PM  
Nov-04-21 12:00PM  
Nov-02-21 05:34PM  
Oct-21-21 08:05PM  
Oct-07-21 03:23PM  
Oct-06-21 01:25PM  
Oct-04-21 07:04PM  
Oct-02-21 06:03AM  
Oct-01-21 02:56PM  
Sep-30-21 05:00PM  
Sep-29-21 10:30PM  
Sep-28-21 06:15PM  
Sep-27-21 07:39PM  
Sep-26-21 11:05PM  
Sep-25-21 02:03AM  
Sep-23-21 12:08PM  
Sep-22-21 06:34PM  
Sep-21-21 05:05PM  
Aug-31-21 04:05PM  
Aug-11-21 04:05PM  
Aug-02-21 12:15PM  
Jul-30-21 06:48AM  
Jul-22-21 04:05PM  
Jul-15-21 08:33AM  
Jul-12-21 08:33AM  
Jun-28-21 08:33AM  
Jun-07-21 04:15PM  
May-27-21 08:33AM  
May-11-21 04:05PM  
May-07-21 07:59AM  
May-05-21 04:05PM  
Apr-30-21 03:40PM  
Apr-26-21 08:33AM  
Apr-23-21 11:15AM  
Apr-21-21 06:05AM  
Apr-20-21 05:16PM  
Apr-19-21 07:00AM  
Apr-16-21 08:33AM  
Apr-13-21 04:35PM  
Apr-06-21 08:33AM  
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sagartz John EChief Strategy OfficerJun 07Buy28.701,74249,995648,524Jun 08 04:10 PM
Sagartz John EChief Strategy OfficerMay 28Buy24.782,01249,857646,782Jun 01 04:01 PM
Sagartz John EChief Strategy OfficerMay 27Buy24.005120644,770Jun 01 04:01 PM
Taylor BethVP- Finance & CFOMay 13Buy23.142,15449,84437,329May 17 04:01 PM
Beattie John GregoryChief Operating OfficerMay 13Buy22.915,000114,55030,440May 17 04:01 PM
Pitchford William DChief HR OfficerMay 13Buy23.721,50035,58041,921May 17 04:02 PM